Catalyst Biosciences
Biotechnology, 611 Gateway BLVD, South San Francisco, California, 94080, United States, 51-200 Employees
Phone Number: 65********
Who is CATALYST BIOSCIENCES
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protea...
Read More
-
Headquarters: 611 Gateway BLVD, South San Francisco, California, 94080, United States
-
Date Founded: 1997
-
Employees: 51-200
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from CATALYST BIOSCIENCES
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Catalyst Biosciences
Answer: Catalyst Biosciences's headquarters are located at 611 Gateway BLVD, South San Francisco, California, 94080, United States
Answer: Catalyst Biosciences's phone number is 65********
Answer: Catalyst Biosciences's official website is https://catalystbiosciences.com
Answer: Catalyst Biosciences's revenue is $100 Million to $250 Million
Answer: Catalyst Biosciences's SIC: 2836
Answer: Catalyst Biosciences's NAICS: 325414
Answer: Catalyst Biosciences has 51-200 employees
Answer: Catalyst Biosciences is in Biotechnology
Answer: Catalyst Biosciences contact info: Phone number: 65******** Website: https://catalystbiosciences.com
Answer: Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month